Future perspectives in the treatment of psoriasis

Current Problems in Dermatology

Volumn 38, Issue , 2009, Pages 172-189

  Wippel Slupetzky, K ^a   Stingl, G ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ABATACEPT; ABT 874; AE 941; APREMILAST; BIMOSIAMOSE; BMS 582949; CC 1004; CE 224535; CYCLOSPORIN; DENILEUKIN DIFTITOX; FONTOLIZUMAB; GALIXIMAB; GOLIMUMAB; HUMAB 10F8; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; RECOMBINANT INTERLEUKIN 10; SOTRASTAURIN; TOCILIZUMAB; UNCLASSIFIED DRUG; USTEKINUMAB; VOCLOSPORIN; ENZYME INHIBITOR; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; NEW DRUG; SIGNAL PEPTIDE;

ANGIOGENESIS; CELL TRANSPORT; CLINICAL TRIAL; DOSE RESPONSE; DRUG BINDING; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNE RESPONSE; LEUKOCYTE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; DRUG ANTAGONISM; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PSORIASIS; SIGNAL TRANSDUCTION;

EID: 70350492774     PISSN: 14215721     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000232310     Document Type: Review

References (63)

1. McKenzie RC, Sabin E: Aberrant signalling and transcription factor activation as an explanation for the defective growth control and differentiation of keratinocytes in psoriasis: a hypothesis (review). Exp Dermatol 2003;12:337-345.
2. Ortonne JP: Recent developments in the understanding of the pathogenesis of psoriasis (review). Br J Dermatol 1999;140(suppl 54):1-7.
3. Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, Scheuch H, Angel P, Tschachler E, Wagner EF: Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005;437:369-375.
4. Prinz JC: Disease mimicry -a pathogenetic concept for T cell-mediated autoimmune disorders triggered by molecular mimicry (review)? Autoimmun Rev 2005;3:10-15.
5. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, Burg G, Liu Y-J, Gilliet M: Plasmacytoid predendritic cells initiate psoriasis through interferon-a production. J Exp Med 2005; 202:135-143.
6. Mommers JM, van Rossum MM, van Erp PE, van de Kerkhof PC: Changes in keratin 6 and keratin 10 (co-) expression in lesional and symptomless skin of spreading psoriasis. Dermatology 2000;201:15-20.
7. O'Neill LA: Targeting signal transduction as a strategy to treat inflammatory diseases (review). Nat Rev Drug Discov 2006;5:549-563.
8. Schneider MR, Werner S, Paus R, Wolf E: Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology (review). Am J Pathol 2008;173:14-24.
9. Miyagawa S, Fujimoto H, Ko S, Hirota S, Kitamura Y: Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. Br J Dermatol 2002;147:406-407.
10. Robinson MJ, Cobb MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-186.
11. Roux PP, Blenis J: ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions (review). Microbiol Mol Biol Rev 2004;68:320-344.
12. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Keys JR, Land Vatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-746.
13. Johansen C, Kragballe K, Westergaard M, Henningsen J, Kristiansen K, Iversen L: The mito-gen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 2005;152:37-42.
14. Ding C: Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr Opin Investig Drugs 2006;7: 1020-1025.
15. O'Shea JJ, Pesu M, Borie DC, Changelian PS: A new modality for immunosuppression: targeting the Jak/ Stat pathway (review). Nat Rev Drug Discov 2004;3: 555-564.
16. Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, Itami S, Nickoloff BJ, DiGiovanni J: Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005;11:43-49.
17. Skvara H, Dawid M, Kleyn E, Wolff B, Meingasser JG, Knight H, Dumortier T, Kopp T, Fallahi N, Stary G, Burkhart C, Grenet O, Wagner J, Hijazi Y, Morris RE, McGeown C, Rordorf C, Griffiths CE, Stingl G, Jung T: The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest 2008;118: 3151-3159.
18. Bos JD, Meinardi MM, van Joost T, heule F, Powles AV, Fry L: Use of cyclosporin in psoriasis (review). Lancet 1989;2:1500-1502.
19. Haider AS, Lowes MA, Suarez-Farinas M, Zaba LC, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG: Identification of cellular pathways of 'type 1,' Th17 T cells, and TNF-and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacog-enomic study of cyclosporine A in psoriasis. J Immunol 2008;180:1913-1920.
20. Papp K, Bissonnette R, Rosoph L, Wasel N, Lynde CW, Searles G, Shear NH, Huizinga RB, Maksymowych WP: Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1337-1342.
21. Weinshenker BG, Bass BH, Ebers GC, Rice GP: Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. Am Acad Dermatol 1989;20:1132-1133.
22. Gottlieb AB, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G, Solodkina G, Grossman R, Gisoldi E, Philips S, Neisler HM, Krueger JG: Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 2000;43:595-604.
23. Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW, Crosby D, Faust H, Fivenson D, Nichols J: Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol 1998;38:938-944.
24. June CH, Ledbetter JA, Linsley PS, Thompson CB: Role of the CD28 receptor in T-cell activation. Immunol Today 1990;11:211-216.
25. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG, Ochs HD, Kelley SL, Khang S: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-1252.
26. Gottlieb AB, Lebwohl M, Totoritis MC, Abdulghani AA, Shuey SR, Romano P, Chaudhari U, Allen RS, Lizambri RG: Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. J Am Acad Dermatol 2002;47:692-700.
27. Ghoreschi K, Rocken M: Immune deviation strategies in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:193-198.
28. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, van der Zee R, Biedermann T, Prinz J, Mack M, Mrowietz U, Christophers E, Schlondorff D, Plewig G, Sander CA, Rocken M: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003;9:40-46.
29. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, Docke WD: IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998;101:783-794.
30. Shreedhar V, Giese T, Sung VW, Ullrich SE: A cytokine cascade including prostaglandin E2, IL-4, and IL-10 is responsible for UV-induced systemic immune suppression. J Immunol 1998;160:3783-3789.
31. Michel G, Gailis A, Jarzebska-Deussen B, Muschen A, Mirmohammadsadegh A, Ruzicka T: 1,25-(OH)2-vitamin D3 and calcipotriol induce IL-10 receptor gene expression in human epidermal cells. Inflamm Res 1997;46:32-34.
32. Asadullah K, Docke WD, Ebeling M, Friedrich M, Belbe G, Audring H, Volk HD, Sterry W: Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol 1999;135:187-192.
33. Reich K, Bruck M, Grafe A, Vente C, Neumann C, Garbe C: Treatment of psoriasis with interleukin-10. J Invest Dermatol 1998;111:1235-1236.
34. Kimball AB, Kawamura T, Tejura K, Boss C, Hancox AR, Vogel JC, Steinberg SM, Turner ML, Blauvelt A: Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. Arch Dermatol 2002;138:1341-1346.
35. Friedrich M, Docke WD, Klein A, Philipp S, Volk HD, Sterry W, Asadullah K: Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. J Invest Dermatol 2002;118:672-677.
36. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang Y-H, Wang Y, Hood L, Zhu Z, Tian Q, Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-1141.
37. McKenzie BS, Kastelein RA, Cua DJ: Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006;27:17-23.
38. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, PHOENIX 1 study investigators: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371: 1665-1674. (Pubitemid 351671883)
39. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K, PHOENIX 2 study investigators: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-1684. (Pubitemid 351671884)
40. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J, ABT-874 Psoriasis Study Investigators: Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144:200-207.
41. Lee E, Trepicchio WL, Osterreicher JL, Pittman D, Wang F, Chamian F, Dhodapkar M, Krueger JG: Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-130.
42. Kavanaugh A, McInnes I ,Mease P: Golimumab, a new human TNF-alpha antibody administered as a monthly subcutaneous injection in psoriatic arthritis: 24 week efficacy and safety results of the randomized, placebo controlled GO-REVEAL study. Abstract 62nd Eur League Rheum, Paris, 2008.
43. Lew W, Bowcock AM, Krueger JG: Psoriasis vul-garis: cutaneous lymphoid tissue supports T-cell activation and 'type 1' inflammatory gene expression. Trends Immunol 2004;25:295-305.
44. Gomi T, Shiohara T, Munataka T, Imanishi K, Nagashima M: IL-1a, TNF-a and IFN-y in psoriasis. Arch Dermatol 1991;127:827-830.
45. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ: The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type-1 cell-mediated response. J Invest Dermatol 1993;101:701-705.
46. Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zakuciova M, D'Haens G, Van Assche G, Ba S, Lee S, Pearce T: Fontolizumab, a humanised anti-interferon-gamma antibody, demonstrates safety and potential clinical activity in patients with moderate to severe Crohn's disease. Gut 2006;55:1131-1137.
47. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-238.
48. Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, Kupper TS, Sehgal PB, Gottlieb AB: Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989;86:6367-6371.
49. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-2829.
50. Harada A, Mukaida N, Matsushima K: Interleukin 8 as a novel target for intervention therapy in acute inflammatory diseases. Mol Med Today 1996;2:482-489.
51. Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ: Purification of a human monocyte-derived neutro-phil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 1987;84:9233-9237.
52. Tuschil A, Lam C, Haslberger A, Lindley I: Interleukin-8 stimulates calcium transients and promotes epidermal cell proliferation. J Invest Dermatol 1992;99:294-298.
53. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-1801.
54. Homey B: Chemokines and chemokine receptors as targets in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:169-174.
55. Skov L, Beurskens FJ, Zachariae C, Reitamo S, Teeling J, Satijn D, Knudsen KM, Boot E, Hudson D, Baadsgaard O, Parren P, van de Winkel: IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustu-losis. J Immunol 2008;181:669-679.
56. Gutzmer R, Langer K, Mommert S, Wittmann M, Kapp A, Werfel T: Human dendritic cells express the IL-18R and are chemoattracted to IL-18. J Immunol 2003;171:6363-6371.
57. Naik SM, Cannon G, Burbach GJ, Singh SR, Swerlick RA, Wilcox JN, Ansel JC, Caughman SW: Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene. J Invest Dermatol 1999;113: 766-772.
58. Nakahira M, Ahn HJ, Park WR, Gao P, Tomura M, Park CS, Hamaoka T, Ohta T, Kurimoto M, Fujiwara H: Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol 2002;168:1146-1153.
59. Friedrich M, Bock D, Philipp S, Ludwig N, Sabat R, Wolk K, Schroeter-Maas S, Aydt E, Kang S, Dam TN, Zahlten R, Sterry W, Wolff G: Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch Dermatol Res 2006;297:345-351.
60. Schon MP, Krahn T, Schon M, Rodriguez ML, Antonicek H, Schultz JE, Ludwig RJ, Zollner TM, Bischoff E, Bremm KD, Schramm M, Henninger K, Kaufmann R, Gollnick HP, Parker CM, Boehncke WH: Efomycine M, a new specific inhibitor of selec-tin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med 2002;8:366-372.
61. Heidenreich R, Rocken M, Ghoreschi K: Angio-genesis: the new potential target for the therapy of psoriasis? Drug News Perspect 2008;21:97-105.
62. Detmar M, Brown LF, Schon MP, Elicker BM, Velasco P, Richard L, Fukumura D, Monsky W, Claffey KP, Jain RK: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998;111:1-6.
63. Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, Tak PP: Deactivation of endothelium and reduction in angiogenesis in pso-riatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004;6:R326-R334.